TFG-RARA: A novel fusion gene in acute promyelocytic leukemia that is responsive to all-trans retinoic acid

Acute promyelocytic leukemia (APL) is classically characterized by the promyelocytic leukemia-retinoic acid receptor α (PML-RARA) fusion, which is the consequence of t(15;17)(q24;q21) chromosomal translocation [1,2]. In rare instances, RARA had been observed to fuse with other partners such as ZBTB16, NUMA, STAT5B, PRKAR1a, BCOR, FIP1L1, NPM and TBLR1[3–5]. Confirmation of RARA-fusion not only provides informat ion on the responsiveness to all-trans retinoic acid (ATRA) treatment, but also a means to detect minimal residual disease (MRD) and monitor disease progression [6,7].
Source: Leukemia Research - Category: Hematology Authors: Tags: Correspondence Source Type: research